These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28117555)

  • 1. Biomarker classification, validation, and what to look for in 2017 and beyond.
    Davis JW
    BJU Int; 2017 May; 119(5):812-814. PubMed ID: 28117555
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of immunotherapy for urological tumours.
    Hrouda D; Muir GH; Dalgleish AG
    Br J Urol; 1997 Mar; 79(3):307-16. PubMed ID: 9117206
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of immunotherapy in urologic malignancies.
    Abubakr YA; Redman BG
    Cancer Treat Res; 1996; 88():235-48. PubMed ID: 9239484
    [No Abstract]   [Full Text] [Related]  

  • 4. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies].
    Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S
    Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
    Chaudhary UB; Hull GW
    Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological response modifiers and urological cancer].
    Ohmori H; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1992 Jun; 83(6):850-6. PubMed ID: 1501395
    [No Abstract]   [Full Text] [Related]  

  • 7. [Are immunotherapy and chemotherapy in metastatic renal cell cancer out?].
    Schmitz-Dräger BJ
    Urologe A; 1992 Jul; 31(4):213-4. PubMed ID: 1514204
    [No Abstract]   [Full Text] [Related]  

  • 8. Present status of cancer treatment in Singapore-management of urological cancers.
    Tun KH; Tan EC; Foo KT
    Gan To Kagaku Ryoho; 1992 Jul; 19(8 Suppl):1139-45. PubMed ID: 1514826
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current modalities in immunotherapy of renal cell carcinoma].
    Aliaev IuG; Grigorian VA; Shpot' EV
    Ter Arkh; 2007; 79(6):78-82. PubMed ID: 17684975
    [No Abstract]   [Full Text] [Related]  

  • 10. Metastasectomy plus immunotherapy compared with immunotherapy alone in metastatic renal cell carcinoma.
    Ku JH; Kwak C
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):164-5. PubMed ID: 17355116
    [No Abstract]   [Full Text] [Related]  

  • 11. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.
    Leppert JT; Lam JS; Belldegrun AS
    J Immunother; 2005; 28(5):427-9. PubMed ID: 16113598
    [No Abstract]   [Full Text] [Related]  

  • 14. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients.
    Négrier S
    J Clin Oncol; 2004 Apr; 22(7):1174-6. PubMed ID: 14981101
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic factors in renal cell cancer.
    Park WH; Eisen T
    BJU Int; 2007 May; 99(5 Pt B):1277-81. PubMed ID: 17441924
    [No Abstract]   [Full Text] [Related]  

  • 16. Integration of surgery and systemic therapy for renal cell carcinoma.
    Kenney PA; Wood CG
    Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyruvate kinase type tumor M2 in urological malignancies.
    Hegele A; Varga Z; Kosche B; Stief T; Heidenreich A; Hofmann R
    Urol Int; 2003; 70(1):55-8. PubMed ID: 12566817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role for metformin in urologic oncology.
    Sayyid RK; Fleshner NE
    Investig Clin Urol; 2016 May; 57(3):157-64. PubMed ID: 27195314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal cell carcinoma: urologists in a new era.
    Uzzo RG
    J Urol; 2005 Nov; 174(5):1723-4. PubMed ID: 16217270
    [No Abstract]   [Full Text] [Related]  

  • 20. [Update on the medical treatment of urologic tumors].
    Culine S
    Bull Cancer; 2000 Jan; 87(1):71-5. PubMed ID: 10673634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.